This Day On The Street
Continue to site
This account is pending registration confirmation. Please click on the link within the confirmation email previously sent you to complete registration.
Need a new registration confirmation email? Click here

Ultragenyx Pharmaceutical Inc (RARE)

NASDAQ: Health Care

Company Cash Flow
Dec 2014 Dec 2013 Dec 2012
Cash Flow From Operating Activities
Net Income (Loss) -59.80M -35.07M -16.33M
Operating Gains/Losses 0.00 0.00 0.00
Extraordinary Gains / Losses 0.00 0.00 0.00
(Increase) Decrease In Receivables 0.00 0.00 3.00K
(Increase) Decrease in Inventories 0.00 0.00 0.00
(Increase) Decrease In Other Current Assets 0.00 0.00 0.00
(Decrease) Increase In Payables 3.18M 237.00K 858.00K
(Decrease) Increase In Other Current Liabilities 3.48M 2.43M 1.50M
(Increase) Decrease In Other Working Capital -411.00K -2.62M 8.00K
Other Non-Cash Items 8.72M 3.56M 1.19M
Net Cash From Continuing Operations -44.63M -31.20M -12.50M
Net Cash From Discontinued Operations 0.00 0.00 0.00
Cash Provided By Investing Activities
Net Cash From Total Operating Activities -44.63M -31.20M -12.50M
Sale of Property, Plant & Equipment 0.00 0.00 0.00
Cash Used for Investing Activities
Sale of Short-Term Investments 0.00 0.00 0.00
Purchases of Property, Plant & Equipment -2.15M -407.00K -1.09M
Acquisitions 0.00 0.00 0.00
Purchases of Short-Term Investments 0.00 0.00 0.00
Other Cash from Investing Activities -293.00K 25.00K -100.00K
Cash Provided by Financing Activities
Net Cash From Investing Activities -123.44M -47.73M -1.19M
Issuance of Debt 0.00 0.00 100.00K
Cash Used for Financing Activities
Issuance of Capital Stock 189.32M 171.00K 89.14M
Repayment of Long-Term Debt 0.00 0.00 0.00
Repurchase of Capital Stock 0.00 0.00 0.00
Payment of Cash Dividends -4.35M 0.00 0.00
Other Financing Charges, Net 0.00 0.00 0.00
Net Cash From Financing Activities 184.97M 171.00K 89.24M
Effect of Exchange Rate Changes 0.00 0.00 0.00
Net Change in Cash & Cash Equivalents 16.90M -78.76M 75.55M

Check Out Our Best Services for Investors

Action Alerts PLUS

Portfolio Manager Jim Cramer and Director of Research Jack Mohr reveal their investment tactics while giving advanced notice before every trade.

Product Features:
  • $2.5+ million portfolio
  • Large-cap and dividend focus
  • Intraday trade alerts from Cramer
Quant Ratings

Access the tool that DOMINATES the Russell 2000 and the S&P 500.

Product Features:
  • Buy, hold, or sell recommendations for over 4,300 stocks
  • Unlimited research reports on your favorite stocks
  • A custom stock screener
Stocks Under $10

David Peltier uncovers low dollar stocks with serious upside potential that are flying under Wall Street's radar.

Product Features:
  • Model portfolio
  • Stocks trading below $10
  • Intraday trade alerts
14-Days Free
Only $9.95
14-Days Free
Dividend Stock Advisor

David Peltier identifies the best of breed dividend stocks that will pay a reliable AND significant income stream.

Product Features:
  • Diversified model portfolio of dividend stocks
  • Updates with exact steps to take - BUY, HOLD, SELL
Trifecta Stocks

Every recommendation goes through 3 layers of intense scrutiny—quantitative, fundamental and technical analysis—to maximize profit potential and minimize risk.

Product Features:
  • Model Portfolio
  • Intra Day Trade alerts
  • Access to Quant Ratings
Real Money

More than 30 investing pros with skin in the game give you actionable insight and investment ideas.

Product Features:
  • Access to Jim Cramer's daily blog
  • Intraday commentary and news
  • Real-time trading forums
Only $49.95
14-Days Free
14-Days Free

RARE Ultragenyx Pharmaceutical Inc

Chart of RARE

Analysts Ratings for RARE

Rating Current 1-Mo Ago 2-Mo Ago 3-Mo Ago
Strong Buy 6 6 6 6
Moderate Buy 1 1 1 0
Hold 1 1 1 1
Moderate Sell 0 0 0 0
Strong Sell 0 0 0 0

RARE Chatter

Top Rated Stocks Top Rated Funds Top Rated ETFs